Source comparison
BPC-157 Wound Healing Protocol: Timeline Comparison
Days 1–3 (Inflammatory Phase) Wound debridement, sterile dressing, inflammation peaks Same baseline care + BPC-157 injection once daily BPC-157 does not reduce inflammation significantly. Neutrophil infiltration and cytokine release proceed normally. Start dos
This comparison does not assign a generated winner or score.
- Days 1–3 (Inflammatory Phase)
- Wound debridement, sterile dressing, inflammation peaks
- Same baseline care + BPC-157 injection once daily
- BPC-157 does not reduce inflammation significantly. Neutrophil infiltration and cytokine release proceed normally. Start dosing here to prime VEGF pathways before proliferative phase begins.
- Days 4–14 (Proliferative Phase)
- Granulation tissue forms, wound contracts 2–3mm/day
- Granulation accelerates (3.5–4.5mm/day), capillary density increases 300%
- Marginal additional benefit (4–5mm/day). Receptor saturation limits further gains
- This is the critical window. VEGF upregulation peaks here. Missing doses during days 5–10 negates 60% of protocol benefit.
- Days 15–21 (Remodelling Phase)
- Collagen remodelling begins, scar tissue matures slowly
- Collagen Type III → Type I transition accelerated by 40%, tensile strength improves earlier
- Similar to 10mcg/kg. Dose escalation provides no measurable advantage in late remodelling
- Higher doses do not improve long-term scar quality. The structural outcome is determined during proliferation, not remodelling.
- Total Healing Time (Full Epithelialisation)
- 21–28 days for deep dermal wounds
- 14–18 days for comparable wounds
- 13–17 days. Statistically significant but clinically marginal vs 10mcg/kg
- 10mcg/kg is the optimal dose for most injury types. Escalating to 20mcg/kg adds cost without proportional benefit unless injury exceeds 10 cm² surface area.